{"id":"W3013900427","doi":"10.1158/1538-7445.sabcs19-p1-19-03","title":"Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Cohort; Metastatic breast cancer; Oncology; Breast cancer; Regimen; PARP inhibitor; Avelumab; Cancer; Immunotherapy; Pembrolizumab; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001911641,0.001149961,0.001276904,0.0003569992,0.0004063633,0.001122582,0.0008509552,0.0009379775,0.004711504],"category_scores_gemma":[0.0007445705,0.0004861277,0.0009958816,0.0003361781,0.0005355804,0.0007679976,0.0003967242,0.002734478,0.001078591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009202132,"about_ca_system_score_gemma":0.001627725,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000833807,"about_ca_topic_score_gemma":0.002867497,"domain_scores_codex":[0.9994992,0.0002290203,0.00002580477,0.0001077338,0.00006531299,0.00007292677],"domain_scores_gemma":[0.9992977,0.00006784205,0.000134204,0.00006021861,0.00006198995,0.0003780297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.598988,0.09058897,0.02259156,0.001283258,0.003152619,0.0004376018,0.0003164744,0.002502229,0.1005936,0.0004915714,0.0270975,0.1519566],"study_design_scores_gemma":[0.5480544,0.3841946,0.03901245,0.00007249165,0.001308026,0.0008147133,0.0001049504,0.00177622,0.01040081,0.0003676332,0.01383449,0.00005918752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98282,0.003078062,0.0006573265,0.001011578,0.0001376711,0.002973195,0.006316189,0.0001907277,0.002815208],"genre_scores_gemma":[0.9652616,0.002978634,0.003981763,0.002135305,0.0002804736,0.003636305,0.0148381,0.00009896515,0.00678895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004711504,"threshold_uncertainty_score":0.01576155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1612202482563175,"score_gpt":0.4793168995785385,"score_spread":0.3180966513222209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}